Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

0.4449 -0.0751 (-14.44%)
Streaming Delayed Price Updated: 1:34 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,459,969
Open 0.4370
Bid (Size) 0.4356 (9)
Ask (Size) 0.4450 (5)
Prev. Close 0.5200
Today's Range 0.4000 - 0.4812
52wk Range 0.3800 - 2.200
Shares Outstanding 32,689,190
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends “FOCUSfactor” Exploding Across North America – More Stocks Inside
Via AB Newswire
Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-53.7%
-53.7%
1 Month
-13.3%
-13.3%
3 Month
-22.5%
-22.5%
6 Month
-55.5%
-55.5%
1 Year
-79.8%
-79.8%

More News

Read More
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
Via Benzinga
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying
Via Benzinga
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024
Via InvestorPlace

Frequently Asked Questions

Is ProMIS Neurosciences Inc. - Common Shares publicly traded?
Yes, ProMIS Neurosciences Inc. - Common Shares is publicly traded.
What exchange does ProMIS Neurosciences Inc. - Common Shares trade on?
ProMIS Neurosciences Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProMIS Neurosciences Inc. - Common Shares?
The ticker symbol for ProMIS Neurosciences Inc. - Common Shares is PMN on the Nasdaq Stock Market
What is the current price of ProMIS Neurosciences Inc. - Common Shares?
The current price of ProMIS Neurosciences Inc. - Common Shares is 0.4449
When was ProMIS Neurosciences Inc. - Common Shares last traded?
The last trade of ProMIS Neurosciences Inc. - Common Shares was at 07/15/25 01:34 PM ET
What is the market capitalization of ProMIS Neurosciences Inc. - Common Shares?
The market capitalization of ProMIS Neurosciences Inc. - Common Shares is 14.54M
How many shares of ProMIS Neurosciences Inc. - Common Shares are outstanding?
ProMIS Neurosciences Inc. - Common Shares has 15M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.